SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-02049

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
PRIVACY	NICARAGUA	16	Aug	2016	8	Female		May	2025	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Pallor (Pallor (10033546), Pallor (10033546))
(/May/2025 -) - Not Recovered/Not Resolved/Ongoing
2) Decreased appetite (Decreased appetite (10061428), Decreased appetite (10061428))
(/May/2025 -) - Not Recovered/Not Resolved/Ongoing
3) Sad, wants to be alone indoors (Feeling sad (10016364), Depressed mood (10012374))
(/May/2025 -) - Not Recovered/Not Resolved/Ongoing

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION
1) (22.5 milligram(s), 1 in 3 Month)	1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Central Precocious Puberty [10073186 - Central precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (03/Feb/2025 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CENTRAL PRECOCIOUS PUBERTY (10073186, Central precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
debbie.maierhofer@tolmar.comand+1-4129158447

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-02049
24c. DATE RECEIVED BY MANUFACTURER: 16/May/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 27/May/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium (reference number: NI-ADIUM-NI-0045-20250516) via Patient Support Program on 16-May-2025 from a consumer (non-health care professional) regarding a 08-year-old female child patient who experienced non-serious events of decreased appetite (Decreased appetite), pallor (Pallor), sad, wants to be alone indoors (Depressed mood) during Eligard (leuprolide acetate) 22.5 mg therapy for central precocious puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 19-May-2025.

The patient's medical history was unknown and current condition included central precocious puberty.

Concomitant medications were unknown.

On 03-Feb-2025, the patient began receiving Eligard 22.5 mg, every 3 months via subcutaneous for central precocious puberty (Lot numbers and Expiration dates were not provided).

On an unknown date in May-2025, the was mild Sad and wanted to be alone indoors. Additionally, she was mild pallor, and her appetite was decreased mildly.

Corrective treatment was not reported.

Action taken with Eligard in response to the events was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of decreased appetite, pallor and depressed mood was not recovered.

The reporter did not assess the seriousness of decreased appetite, pallor, depressed mood.

The reporter assessed the causality of depressed mood as related and decreased appetite; pallor as not related in relationship to Eligard and Eligard Unspecified device.

No follow-up queries raised.

Listedness:

Pallor>Eligard>Unlisted as per CCDS>07-Nov-2024
Pallor>Eligard>Unlisted as per USPI>Feb-2025
Pallor>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Pallor>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Decreased appetite>Eligard>listed as per CCDS>07-Nov-2024
Decreased appetite>Eligard>unlisted as per USPI>Feb-2025
Decreased appetite>Eligard unspecified device>unlisted as per USPI>Feb-2025
Decreased appetite>Eligard>listed as per Canadian monograph>O2-Apr-2025

Depressed mood>Eligard>listed as per CCDS>07-Nov-2024
Depressed mood>Eligard>listed as per USPI>Feb-2025
Depressed mood>Eligard unspecified device>listed as per USPI>Feb-2025
Depressed mood>Eligard>listed as per Canadian monograph>O2-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding a child 08-year-old female patient who experienced pallor (pallor), decreased appetite (decreased appetite) and depressed mood (Sad, wants to be alone indoors) during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. Tolmar assessed the events as non-serious since they did not meet the ICH seriousness criteria and are not IME events. The reported events were assessed as related to Eligard (drug) considering the temporal association of reported events with Eligard administration and known pharmacological profile of the drug (for events decreased appetite and depressed mood).

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	: Eligard® (Leuprolide acetate)
Active Substance	: 1) Leuprolide acetate
Drug Characterization	: Suspect
Form of Admin	: 1) Injection

Continuation Sheet for CIOMS report

Lot Number	:	1) Unknown
Daily Dose	:	(22.5 milligram(s), 1 in 3 Month)
Route of Admin	:	1) Subcutaneous
Indications	:	1) Central Precocious Puberty [10073186 - Central precocious puberty]
Therapy Dates	:	1) From : 03/Feb/2025 To :Continuing
Action(s) Taken With Drug	:	Dose not changed

Causality

1) Pallor (Pallor - 10033546, Pallor - 10033546)

Causality as per reporter	:	Not Related
Causality as per Mfr	:	Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

2) Decreased appetite (Decreased appetite - 10061428, Decreased appetite - 10061428)

Causality as per reporter	:	Not Related
Causality as per Mfr	:	Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

3) Sad, wants to be alone indoors (Feeling sad - 10016364, Depressed mood - 10012374)

Causality as per reporter	:	Related
Causality as per Mfr	:	Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

Labeling :

1) Pallor
CORE UnLabeled

2) Decreased appetite
CORE Labeled

3) Sad, wants to be alone indoors
CORE Labeled

2) Drug	:	Eligard (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Lot Number	:	1) Unknown
Indications	:	1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug	:	Not applicable

Causality

1) Pallor (Pallor - 10033546, Pallor - 10033546)

Causality as per reporter	:	Not Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

2) Decreased appetite (Decreased appetite - 10061428, Decreased appetite - 10061428)

Causality as per reporter	:	Not Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

3) Sad, wants to be alone indoors (Feeling sad - 10016364, Depressed mood - 10012374)

Causality as per reporter	:	Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

Labeling :

1) Pallor
CORE

2) Decreased appetite
CORE

3) Sad, wants to be alone indoors
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Continuation Sheet for CIOMS report

Drug 1 :Eligard®

1) ELIGARD 22.5 MG x 1 LIO x 2 JER